Ainos, Inc.: Form 10-Q for the period ended Jun 30, 2023
Filed with the SEC on Aug 11, 2023 and accepted by EDGAR at Aug 11, 2023, 16:15 ET.
Management's discussion and analysis
As filed, 22,161 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The unaudited condensed financial statements and this Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2022 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our 2022 Annual Report. In addition to historical information, this discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These forward-looking statements are subject to risks and uncertainties, including those set forth under “Part I. Item 1A. Risk Factors” in our 2022 Annual Report, “Part II. Item 1A. Risk Factors” in this Quarterly Report, and elsewhere in this Quarterly Report, that could cause actual results to differ materially from historical results or anticipated results.
When used in this Quarterly Report, all references to "Ainos," the "Company," "we," "our" and "us" refer Ainos, Inc.
Overview
Ainos, Inc. (the “Company”, “we” or “us”), incorporated in the State of Texas, is a diversified healthcare company focused on the development of novel point-of-care testing (POCT), therapeutics based on very low-dose interferon alpha (VELDONA), and synthetic RNA-driven preventative medicine. Our products include VELDONA clinical-stage human therapeutics, VELDONA Pet cytoprotein supplements, and telehealth-friendly POCTs.
The Company’s POCT platforms are designed to provide rapid and convenient testing of a broad range of health conditions. Building on its extensive research and development on VELDONA, the Company is focused on commercializing a suite of VELDONA-based products including VELDONA Pet cytoprotein supplements and VELDONA therapeutics for humans.
In 2021 and 2022, the Company acquired intellectual property from controlling shareholder, Ainos Inc., a Cayman Islands corporation (“Ainos KY”), and continues to expand its product portfolio into POCTs. Pivoting from the sales of COVID-19 POCT, the Company is commercializing POCTs that detect volatile organic compounds (VOC) emitted by the body, powered by the Company’s AI Nose technology platform. The Company’s lead VOCT POCT candidate, Ainos Flora, aims to quickly and easily tests female vaginal health and certain common sexually transmitted infections (STIs).
Our Portfolio of Products
Our portfolio of products is currently comprised of the following:
- COVID-19 Antigen Rapid Test Kit. We currently market and sell COVID-19 antigen rapid test kits in Taiwan under emergency use authorization (“EUA”) issued by the Taiwan Federal and Drug Administration (“TFDA”) for healthcare professional use and for self-test use. We market the test kits under the Ainos brand name. The kit is manufactured by TCNT, our product co-developer.
- VOC POCT – Ainos Flora. Our Ainos Flora device, powered by the Company’s proprietary AI Nose technology (“AI Nose”) is currently under clinical study in Taiwan. The device is intended to perform a non-invasive test for female vaginal health and certain common STIs within a few minutes. A companion app is also being developed that enables users to conveniently manage test results. We believe Ainos Flora provides connected, convenient, discreet, rapid testing in a point-of-care setting.
- VOC POCT – Ainos Pen. Our Ainos Pen device is designed to be a cloud-connected, multi-purpose, portable breath analyzer that is intended to monitor health conditions within minutes, powered by AI Nose. We expect consumers to be empowered to share their test results with their physicians through in-person and telehealth medical consultations.
- VOC POCT – CHS430. The CHS430 device, powered by AI Nose, is intended to provide non-invasive testing for ventilator-associated pneumonia within few minutes, as compared to current standard of care invasive culture tests that typically take more than two days to provide results. We plan to be the exclusive sales agent for CHS430, pursuant to our Product Co-Development Agreement with our co-developer, TCNT, who will manufacture the product.
- Very Low-Dose Oral Interferon Alpha (“VELDONA”). VELDONA is a low-dose oral interferon alpha (“IFN-α”) formulation based on nearly four decades of the Company’s research on IFN-α’s broad treatment applications. Our pipeline candidates under development for human indications include thrombocytopenia, Sjögren’s syndrome, aphthous stomatitis, chemotherapy-induced stomatitis, common cold, oral warts for human immunodeficiency virus (HIV) seropositive patients, influenza, oral treatment for COVID-19. We intend to explore various business opportunities, including out-licensing, to advance these indications. •VELDONA Pet. Leveraging our VELDONA technology, we recently launched five VELDONA Pet cytoprotein health supplements for pet dogs and cats. Our VELDONA Pet product line is formulated to address a variety of health issues in dogs and cats, including skin, gum, emotion, discomfort caused by allergies, eye; and weight-related issues. We are currently launching sales and marketing in Taiwan and plan to develop sales and marketing opportunities in other Asian regions and the U.S.A.
- Synthetic RNA (“SRNA”). We are developing a SRNA technology platform in Taiwan with a long-term goal of developing next-generating precision treatments and rapid tests.
17
Table of Contents
An integral part of our operating strategy is to create multiple revenue streams through commercializing our product portfolio and leveraging our intellectual property patents. Our recent launch of VELDONA Pet, a series of health supplements for pet dogs and cats based on VELDONA formulation, is our latest effort to execute the diversification strategy.
In 2023, we are prioritizing sales and marketing of VELDONA Pet, commercializing our lead VOC POCT candidate, Ainos Flora, and pursuing out-licensing of our VELDONA human drug candidates. We are initiating sales and marketing of VELDONA Pet in Taiwan and intend to explore commercial opportunities in other Asian regions and the U.S.A. We recently assigned Topmed International Biotech Co. to exclusively market VELDONA Pet in Taiwan.
As of June 30, 2023, we had available cash and cash equivalents of $1,360,970. We anticipate business revenues and further potential financial support from external sources to fund our operations over the next twelve months. We have based this estimate on assumptions that may prove to be incorrect, and we could exhaust our available capital resources sooner than we expect. See “Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources” for additional information. To finance our continuing operations, we will need to raise additional capital, which cannot be assured.
Impact of COVID-19 on Our Business
Substantially all of our operating revenue comes from the sale of COVID-19 test kits in Taiwan under emergency use authorization. We recently launched new product line called VELDONA Pet. We plan to generate sales revenue from VELDONA Pet initially in Taiwan and explore commercialization opportunities in other Asian regions and the U.S.A.
We believe that during the COVID-19 pandemic, consumers have become increasingly familiar with at-home tests. Moving forward, people may seek additional at-home tests to manage other infections as quickly as possible. Home self-testing and self-collection have been increasingly available for other infections such as vaginal or STIs. We believe this new user behavior, supported by a variety of telehealth platforms, will become increasingly accommodative for our other POCT products as COVID-19 becomes an endemic.
We are continuing to monitor the potential impact of COVID-19, but we cannot be certain the future impact on our business, financial condition, results of operations and prospects.
Results of Operations for Quarter Ended June 30, 2023 (“Q2 2023”) and June 30, 2022 (“Q2 2022”):
| Three months ended June 30, 2023 | 2022 | Change Amount% | ||
|---|---|---|---|---|
| Revenues | $28,555 | $636,627 | $(608,072) | (96%) |
| Cost of revenues | (55,817) | (318,963) | 263,146 | 83% |
| Gross (loss) profit | (27,262) | 317,664 | (344,926) | (109%) |
| Operating expenses: | ||||
| Research and development expenses | 1,671,187 | 1,634,856 | 36,331 | 2% |
| Selling, general and administrative expenses | 618,149 | 627,104 | (8,955) | (1%) |
| Total operating expenses | 2,289,336 | 2,261,960 | 27,376 | 1% |
| Loss from operations | (2,316,598) | (1,944,296) | (372,302) | 19% |
| Non-operating income (expenses), net: | ||||
| Interest expense | (40,311) | (18,796) | (21,515) | 114% |
| Other income, net | 7,182 | 9,060 | (1,878) | (21%) |
| Total non-operating expenses, net | (33,129) | (9,736) | (23,393) | 240% |
| Net loss before income taxes | (2,349,727) | (1,954,032) | (395,695) | 20% |
| Provision for income taxes | - | - | - | - |
| Net loss | $(2,349,727) | $(1,954,032) | $(395,695) | 20% |
18
Table of Contents
Revenues, Cost and Gross Profit (Loss)
The Company reported $28,555, and $636,627 in revenue in Q2 2023 and Q2 2022, respectively, from product sales of Ainos COVID-19 Antigen Rapid Test Kits in Taiwan. The decrease of revenue in Q2 2023 reflected a slowdown of COVID-19 infection in Taiwan which resulted in a decrease in selling price and sales volume.
The cost of revenue relating to product sales in Q2 2023 was $55,817 compared to $318,963 in Q2 2022. The decrease of cost of revenue was due to a decrease in sales volume but offset by an increase in inventory loss.
Gross (loss) profit from product sales in Q2 2023 was $(27,262) as compared to $317,664 in Q2 2022. The gross loss was due to a decrease in sales volume and selling price as well as recognition of inventory loss in Q2 2023.
Research and Development (R&D) Expenses
R&D expenses in Q2 2023 and Q2 2022 were $1,671,187 and $1,634,856, respectively. The slight increase of $36,331 (2%) was due to increased expenses associated with staffing expenditures (including share-based compensation) and professional expense, but offset by a decrease in clinical trial fees. We expect that our R&D expenses related to clinical trials will continue to grow as we further develop VOC POCT and VELDONA drug candidates and increase the pace of clinical trials previously delayed during the COVID-19 pandemic.
The share-based compensation expense and the depreciation and amortization expense in Q2 2023 and Q2 2022 were $1,210,429 and 1,155,754, respectively. When excluding these non-cash expenses, R&D expenses slightly decreased to $460,758 in Q2 2023 from $479,102 in Q2 2022 due to limitations on recruiting patients for clinical trials for VOC POCT and VELDONA human related drug candidates, but offset by an increase in R&D personnel expense.
Selling, General and Administrative (SG&A) Expenses
SG&A expenses were $618,149 and $627,104 in Q2 2023 and Q2 2022, respectively, reflecting a slight decrease of $8,955 (1%).
The share-based compensation expense and the depreciation and amortization expense in Q2 2023 and Q2 2022 were $121,025 and $125,223, respectively. When excluding these non-cash expenses, SG&A expenses slightly decreased to $497,124 in Q2 2023 compared to $501,881 in Q2 2022.
Operating Loss
The Company’s operating loss was $2,316,598 and $1,944,296 in Q2 2023 and Q2 2022, respectively, reflecting a $372,302 (19%) increase in operating loss between the reporting periods. We incurred a gross loss in product sales that did not offset operating expenses. We continued to invest resources to execute our growth strategy and product roadmap to improve our profitability.
19
Table of Contents
Interest Expense
In Q2 2023, interest expense was $40,311 compared to $18,796 in Q2 2022. The increase in interest expense was due to accrued interest for convertible notes issued in March 2023 bearing a higher interest rate.
Net Loss
Net loss was $2,349,727 in Q2 2023 compared to $1,954,032 in Q2 2022, resulting in a $395,695 (20%) increase in net loss attributable to shareholders of our common stock. The net loss was due to a gross loss in product sales post COVID-19 pandemic.
Results of Operations for the Six Months Ended June 30, 2023 (“H1 2023”) and June 30, 2022 (“H1 2022”):
| Six months ended June 30, 2023 | 2022 | Change Amount% | ||
|---|---|---|---|---|
| Revenues | $77,719 | $723,828 | $(646,109) | (89%) |
| Cost of revenues | (156,665) | (360,042) | 203,377 | (56%) |
| Gross (loss) profit | (78,946) | 363,786 | (442,732) | (122%) |
| Operating expenses: | ||||
| Research and development expenses | 3,370,070 | 3,212,310 | 157,760 | 5% |
| Selling, general and administrative expenses | 1,380,614 | 1,178,834 | 201,780 | 17% |
| Total operating expenses | 4,750,684 | 4,391,144 | 359,540 | 8% |
| Loss from operations | (4,829,630) | (4,027,358) | (802,272) | 20% |
| Non-operating income (expenses), net: | ||||
| Interest expense | (49,585) | (35,483) | (14,102) | 40% |
| Other income, net | 9,013 | 8,914 | 99 | 1% |
| Total non-operating expenses, net | (40,572) | (26,569) | (14,003) | 53% |
| Net loss before income taxes | (4,870,202) | (4,053,927) | (816,275) | 20% |
| Provision for income taxes | - | - | ||
| Net loss | $(4,870,202) | $(4,053,927) | $(816,275) | 20% |
Revenues, Cost and Gross Profit (Loss)
The Company reported $77,719 of revenue for the six months ended June 30, 2023, as compared to $723,828 for the six months ended June 30, 2022 from product sales of Ainos COVID-19 Antigen Rapid Test Kits in Taiwan. The decrease of revenue in H1 2023 reflected a slowdown of COVID-19 infection in Taiwan resulting in a decrease in selling price and sales volume.
The cost of revenue relating to product sales for the six months ended June 30, 2023 was $156,665 compared to $360,042 for the six months ended June 30, 2022. The decrease of cost of revenue was due to a decrease in sales volume but offset by an increase of approximately $57,000 in inventory loss and approximately $20,000 in idle manufacturing capacity.
Gross (loss) profit from product sales for the six months ended June 30, 2023 was $(78,946) as compared to $363,786 for the six months ended June 30, 2022. The gross loss was due to a decrease in sales volume and selling price as well as recognition of inventory loss and idle capacity cost in H1 2023.
Research and Development (R&D) Expenses
R&D expenses for the six months ended June 30, 2023 and 2022 were $3,370,070 and $3,212,310, respectively. The $157,760 (5%) increase was largely due to increased expenses associated with staffing expenditures (including share-based compensation) and professional expense, but offset by a decrease in clinical trial fees. We expect that our R&D expenses related to clinical trials will continue to grow as we further develop VOC POCT and VELDONA drug candidates and increase the pace of clinical trials previously delayed during the COVID-19 pandemic.
The share-based compensation expense and the depreciation and amortization expense in H1 2023 and H1 2022 were $2,405,414 and 2,291,966, respectively. When excluding these non-cash expenses, R&D expenses slightly increased to $964,656 in H1 2023 from $920,344 in H1 2022 due to an increase in R&D personnel expense, but offset by a decrease in clinical trial fees due to delays caused by the COVID-19 pandemic.
20
Table of Contents
Selling, General and Administrative (SG&A) Expenses
SG&A expenses were $1,380,614 and $1,178,834 for the six months ended June 30, 2023 and 2022, respectively. The $201,780 (17%) increase was largely due to increased expenses associated with share-based compensation as the Company granted RSUs to employees and board of directors in the second half of 2022 and fully recorded amortized compensation expense in H1 2023.
The share-based compensation expense and the depreciation and amortization expense in H1 2023 and H1 2022 were $327,495 and 145,447, respectively. When excluding these non-cash expenses, SG&A expenses slightly increased to $1,053,119 in H1 2023 compared to $1,033,387 in H1 2022.
Operating Loss
The Company’s operating loss was $4,829,630 and $4,027,358 in H1 2023 and H1 2022, respectively, reflecting an $802,272 (20%) increase in operating losses between the reporting periods. We incurred a gross loss in product sales that did not offset operating expenses. We continued to invest resources to execute our growth strategy and product roadmap to improve our profitability.
Interest Expense
In H1 2023, interest expense was $49,585 compared to $35,483 in H1 2022. The increase in interest expense was due to accrued interest for convertible notes issued in March 2023 offset by a decrease of interest expense as a result of settlement of convertible notes during H1 2023.
Net Loss
Net loss was $4,870,202 in H1 2023 compared to $4,053,927 in H1 2022, resulting in an $816,275 (20%) increase in net loss attributable to our shareholder of common stock. The net loss was due to gross loss in product sales post COVID-19 pandemic while our VEDOLNA Pet sales launched in July 2023.
Liquidity and Capital Resources
As of June 30, 2023 and December 31, 2022, the Company had available cash of $1,360,970 and $1,853,362, respectively.
The following table summarizes our cash flow during the six months period ended June 30, 2023 and 2022:
| Six months ended June 30, 2023 | 2022 | |
|---|---|---|
| Net cash used in operating activities | (2,578,453) | (1,629,278) |
| Net cash used in investing activities | (71,262) | (424,557) |
| Net cash provided by financing activities | 2,185,974 | 2,200,000 |
Operating activities:
Cash used in operating activities increased by $949,175 in H1 2023 compared to H1 2022. Our net loss for H1 2023 increased by $816,275 primarily due to a gross loss from COVID-19 antigen test kit sales as a result of slow-down of COVID-19 infection in Taiwan. The operating cash outflow as a result of changes in operating assets and liabilities was mainly attributable to:
- No cash out expenses including share-based compensation, depreciation and amortization, and loss on inventory write-downs increased approximately by $373,000
- Working capital injected into accounts receivable, inventories and other current assets increased by approximately $1,623,000
- Working capital injected into accrued expenses, lease liabilities and other current and long-term liabilities decreased by approximately $2,129,000.
21
Table of Contents
Investing activities
Cash used for investing activities in H1 2023 was $71,262 compared to $424,557 in H1 2022, respectively, due to lower levels of R&D equipment and office facility acquisition, major investments in 2022.
Financing activities
Cash received from financing activities was $2,185,974 and $2,200,000 in H1 2023 and H1 2022, respectively. The $14,026 decrease was primarily reflected by the following:
- Repayment of convertible notes and other notes payable increased $314,026; but
- Proceeds from convertible notes and other notes payable increased by $300,000.
As disclosed in Note 5 Convertible Notes Payable and Other Notes Payable, we received $2.5 million in proceeds from convertible note financing in March 2023. Meanwhile, we made partial cash payment of the KY Note and Chen Note during H1 2023.
In 2023, we project an increase in the pace of clinical trial spending to advance our VOC POCT and VELDONA drug candidates and expect to invest more in R&D activities. We also plan to allocate sales and marketing efforts for VELDONA Pet.
The Company anticipates that cash reserves, business revenues, and potential debt financing through convertible and non-convertible notes will fund the Company’s operations over the next twelve months. There can be no assurance that we will be successful in our efforts to make the Company profitable. If those efforts are not successful, the Company may raise additional capital through the issuance of equity securities, debt financings or other sources to further implement its business plan. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan.
Critical Accounting Policies and Significant Management Estimates
Our management’s discussion and analysis of our financial condition and results of operations are based on our unaudited condensed financial statements, which have been prepared in accordance with the accounting principles generally accepted in the United States, or U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses.
We evaluate our estimates and judgments, including those related to inventory valuation, useful lives of property and equipment, valuation of stock option and warrants, and impairment testing of intangible assets, on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
There have been no material changes to our critical accounting policies and estimates as compared to the critical accounting policies and estimates disclosed in “Management’s Discussion and Analysis - Critical Accounting Policies and Significant Management Estimates” of our 2022 Annual Report, except for those accounting subjects discussed in the Notes, if any, to the unaudited condensed financial statements included in this Quarterly Report on Form 10-Q.
Market risk
As filed, 191 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this Item 3.
22
Table of Contents
Controls and procedures
As filed, 821 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, have evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on the evaluation of our disclosure controls and procedures, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of June 30, 2023.
Changes in Internal Control over Financial Reporting
There were no changes in our internal controls over financial reporting during the period covered by this Quarterly Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
23
Table of Contents
Risk factors
As filed, 1,307 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
This Quarterly Report contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed in this Quarterly Report. Factors that could cause or contribute to these differences include, but are not limited to, those discussed below and elsewhere in this Quarterly Report.
You should carefully consider the risk factors disclosed in our Form 10-K for the period ended December 31, 2022 (the “2022 Annual Report”), together with all other information in this Quarterly Report, including our unaudited condensed financial statements and notes thereto, and in our other filings with the Securities and Exchange Commission. If any of the following risks, or other risks not presently known to us or that we currently believe to not be significant, develop into actual events, then our business, financial condition, results of operations or prospects could be materially adversely affected. If that happens, the market price of our common stock could decline, and stockholders may lose all or part of their investment.
There are no material changes to the risk factors as previously disclosed in our 2022 Annual Report, incorporated herein by this referenced, which was filed with the Securities and Exchange Commission on April 3, 2023.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-04-01 to 2023-06-30 | $28.6k | us-gaap:Revenues |
| Revenue | 6 months2023-01-01 to 2023-06-30 | $77.7k | us-gaap:Revenues |
| Cost of revenue | 3 months2023-04-01 to 2023-06-30 | $55.8k | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2023-01-01 to 2023-06-30 | $156.7k | us-gaap:CostOfRevenue |
| Gross profit | 3 months2023-04-01 to 2023-06-30 | −$27.3k | us-gaap:GrossProfit |
| Gross profit | 6 months2023-01-01 to 2023-06-30 | −$78.9k | us-gaap:GrossProfit |
| Research and development | 3 months2023-04-01 to 2023-06-30 | $1.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2023-01-01 to 2023-06-30 | $3.4m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2023-04-01 to 2023-06-30 | $618.1k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2023-01-01 to 2023-06-30 | $1.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-04-01 to 2023-06-30 | −$2.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-01-01 to 2023-06-30 | −$4.8m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2023-04-01 to 2023-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2023-01-01 to 2023-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-04-01 to 2023-06-30 | −$2.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-01-01 to 2023-06-30 | −$4.9m | us-gaap:NetIncomeLoss |
| Operating cash flow | 6 months2023-01-01 to 2023-06-30 | −$2.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2023-06-30 | $1.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-06-30 | $2.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-06-30 | $34.0m | us-gaap:Assets |
| Current liabilities | At period end2023-06-30 | $1.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-06-30 | $3.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-06-30 | $30.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001654954-23-010601. Last ingested by Listed: Nov 11, 2026, 00:28 ET. Listed shows no prices and gives no investment advice.